KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
AcquisitionsCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionDividends Paid - CommonExchange Rate EffectFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Quest Diagnostics (DGX) Gains from Investment Securities (2016 - 2025)

Quest Diagnostics' Gains from Investment Securities history spans 17 years, with the latest figure at -$11.0 million for Q3 2025.

  • For Q3 2025, Gains from Investment Securities changed N/A year-over-year to -$11.0 million; the TTM value through Sep 2025 reached $2.0 million, changed N/A, while the annual FY2024 figure was $24.0 million, N/A changed from the prior year.
  • Gains from Investment Securities for Q3 2025 was -$11.0 million at Quest Diagnostics, down from -$5.0 million in the prior quarter.
  • Across five years, Gains from Investment Securities topped out at $29.0 million in Q3 2023 and bottomed at -$48.0 million in Q4 2021.
  • The 5-year median for Gains from Investment Securities is -$5.0 million (2024), against an average of -$5.0 million.
  • The largest annual shift saw Gains from Investment Securities surged 2500.0% in 2021 before it crashed 400.0% in 2024.
  • A 5-year view of Gains from Investment Securities shows it stood at -$48.0 million in 2021, then surged by 39.58% to -$29.0 million in 2022, then skyrocketed by 200.0% to $29.0 million in 2023, then crashed by 117.24% to -$5.0 million in 2024, then tumbled by 120.0% to -$11.0 million in 2025.
  • Per Business Quant, the three most recent readings for DGX's Gains from Investment Securities are -$11.0 million (Q3 2025), -$5.0 million (Q2 2024), and -$11.0 million (Q1 2024).